daunorubicin has been researched along with buparlisib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bukum, N; Hofman, J; Morell, A; Novotna, E; Wsol, V | 1 |
1 other study(ies) available for daunorubicin and buparlisib
| Article | Year |
|---|---|
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Topics: Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Aminopyridines; Binding Sites; Catalytic Domain; Daunorubicin; HCT116 Cells; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Morpholines; Recombinant Proteins | 2019 |